Vision-Sciences Inc (VSCI) Reports Q1 Loss of $0.04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Vision-Sciences Reports First Quarter Fiscal 2015 Results
August 4, 2014 4:30 PM EDTORANGEBURG, N.Y., Aug. 4, 2014 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq: VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath® technology, today announced financial results for the first quarter of fiscal 2015, ended June 30, 2014.
First Quarter Fiscal Year 2015 Highlights
Net sales increased 3% to $3.8 million as compared with $3.7 million in first quarter of fiscal 2014; Operating loss improved 21% to $(1.9) million; Net loss improved by 19% to $(2.0) million, or ($0.04) per basic and diluted share; and Vision-Sciences chose not to renew an agreement with Stryker Corporation for the... More